• Je něco špatně v tomto záznamu ?

A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects

VS. Blanchette, L. Zunino, V. Grassmann, C. Barnes, MD. Carcao, J. Curtin, S. Jackson, L. Khoo, V. Komrska, D. Lillicrap, M. Morfini, G. Romanova, D. Stephens, E. Zapotocka, ML. Rand, J. Blatny

. 2021 ; 121 (10) : 1326-1336. [pub] 20210127

Jazyk angličtina Země Německo

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012180

Grantová podpora
Baxalta/Takeda #IIRH15-27025
Baxalta U.S. Inc. #IIRH15-27025

Standard pharmacokinetic (PK) assessments are demanding for persons with hemophilia A, requiring a 72-hour washout and 5 to 11 timed blood samples. A no-washout, single-clinic visit, sparse sampling population PK (PPK) protocol is an attractive alternative. Here, we compared PK parameters obtained with a traditional washout, 6-sampling time point PPK protocol with a no-washout, single-clinic visit, reverse 2-sampling time point PPK protocol in persons with severe hemophilia A (SHA) receiving ADVATE. A total of 39 inhibitor-negative males with SHA (factor VIII activity [FVIII:C] < 2%) were enrolled in a prospective sequential design PK study. Participants completed a washout, 6-sampling time point PPK protocol as well as a no-washout, reverse 2-sampling time point protocol, with samples taken during a single 3-hour clinic visit 24 hours post home infusion of FVIII and then 3 hours post infusion in clinic. FVIII:C levels were analyzed by one-stage and chromogenic assays; blood group and von Willebrand factor antigen (VWF:Ag) were determined; and PK parameters were analyzed using the ADVATE myPKFiT dosing tool. There was moderate to almost perfect agreement for the PK parameters obtained with the 2- and the 6- point PPK protocols using a one-stage FVIII:C assay and a substantial to almost perfect agreement using a chromogenic FVIII:C assay. Significant associations between specific PK parameters and blood group and VWF:Ag were observed. The no-washout, single-clinic visit, reverse 2-sampling time point PPK protocol can be used in the routine clinical setting since it demonstrates sufficient accuracy compared with the more demanding and less practical washout, 6-sampling time point PPK protocol in persons with SHA receiving ADVATE.

Child Health Evaluative Sciences Research Institute The Hospital for Sick Children Toronto Ontario Canada

Department of Biochemistry University of Toronto Toronto Ontario Canada

Department of Clinical Haematology University Hospital Brno Brno Czech Republic

Department of Clinical Research Services The Hospital for Sick Children Toronto Canada

Department of Haematology The Children's Hospital at Westmead Sydney Australia

Department of Laboratory Medicine and Pathobiology University of Toronto Toronto Ontario Canada

Department of Paediatric Haematology and Oncology University Hospital Motol Prague Czech Republic

Department of Paediatric Haematology University Hospital Brno Brno Czech Republic

Department of Paediatrics and Child Health University of Sydney Sydney Australia

Department of Paediatrics University of Toronto Toronto Ontario Canada

Department of Pathology and Molecular Medicine Queen's University Kingston Ontario Canada

Division of Haematology Oncology The Hospital for Sick Children Toronto Ontario Canada

Division of Haematology St Paul's Hospital Vancouver British Columbia Canada

Faculty of Medicine Masaryk University Brno Czech Republic

Haematology Department Royal Prince Alfred Hospital NSW Health Pathology Sydney Australia

Haematology Department The Royal Children's Hospital Melbourne Victoria Australia

Haematology Research Murdoch Children's Research Institute Victoria Australia

Italian Association of Haemophilia Centres Florence Italy

Translational Medicine Research Institute The Hospital for Sick Children Toronto Canada

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012180
003      
CZ-PrNML
005      
20220506130210.0
007      
ta
008      
220425s2021 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1055/a-1376-0970 $2 doi
035    __
$a (PubMed)33506480
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Blanchette, Victor S $u Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada $u Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada
245    12
$a A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects / $c VS. Blanchette, L. Zunino, V. Grassmann, C. Barnes, MD. Carcao, J. Curtin, S. Jackson, L. Khoo, V. Komrska, D. Lillicrap, M. Morfini, G. Romanova, D. Stephens, E. Zapotocka, ML. Rand, J. Blatny
520    9_
$a Standard pharmacokinetic (PK) assessments are demanding for persons with hemophilia A, requiring a 72-hour washout and 5 to 11 timed blood samples. A no-washout, single-clinic visit, sparse sampling population PK (PPK) protocol is an attractive alternative. Here, we compared PK parameters obtained with a traditional washout, 6-sampling time point PPK protocol with a no-washout, single-clinic visit, reverse 2-sampling time point PPK protocol in persons with severe hemophilia A (SHA) receiving ADVATE. A total of 39 inhibitor-negative males with SHA (factor VIII activity [FVIII:C] < 2%) were enrolled in a prospective sequential design PK study. Participants completed a washout, 6-sampling time point PPK protocol as well as a no-washout, reverse 2-sampling time point protocol, with samples taken during a single 3-hour clinic visit 24 hours post home infusion of FVIII and then 3 hours post infusion in clinic. FVIII:C levels were analyzed by one-stage and chromogenic assays; blood group and von Willebrand factor antigen (VWF:Ag) were determined; and PK parameters were analyzed using the ADVATE myPKFiT dosing tool. There was moderate to almost perfect agreement for the PK parameters obtained with the 2- and the 6- point PPK protocols using a one-stage FVIII:C assay and a substantial to almost perfect agreement using a chromogenic FVIII:C assay. Significant associations between specific PK parameters and blood group and VWF:Ag were observed. The no-washout, single-clinic visit, reverse 2-sampling time point PPK protocol can be used in the routine clinical setting since it demonstrates sufficient accuracy compared with the more demanding and less practical washout, 6-sampling time point PPK protocol in persons with SHA receiving ADVATE.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a ambulantní péče $7 D000553
650    _2
$a hemokoagulace $x účinky léků $7 D001777
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a klinické protokoly $7 D002985
650    _2
$a koagulancia $x aplikace a dávkování $x krev $x farmakokinetika $7 D003029
650    12
$a monitorování léčiv $7 D016903
650    _2
$a faktor VIII $x aplikace a dávkování $x farmakokinetika $7 D005169
650    _2
$a hemofilie A $x krev $x diagnóza $x farmakoterapie $7 D006467
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a biologické modely $7 D008954
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a prospektivní studie $7 D011446
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Austrálie $7 D001315
651    _2
$a Kanada $7 D002170
651    _2
$a Česká republika $7 D018153
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Zunino, Laura $u Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada
700    1_
$a Grassmann, Viviane $u Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada
700    1_
$a Barnes, Chris $u Haematology Department, The Royal Children's Hospital Melbourne, Victoria, Australia $u Haematology Research, Murdoch Children's Research Institute, Victoria, Australia
700    1_
$a Carcao, Manuel D $u Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada $u Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada
700    1_
$a Curtin, Julie $u Department of Haematology, The Children's Hospital at Westmead, Sydney, Australia $u Department of Paediatrics and Child Health, University of Sydney, Sydney, Australia
700    1_
$a Jackson, Shannon $u Division of Haematology, St. Paul's Hospital, Vancouver, British Columbia, Canada
700    1_
$a Khoo, Liane $u Haematology Department, Royal Prince Alfred Hospital, NSW Health Pathology, Sydney, Australia
700    1_
$a Komrska, Vladimir $u Department of Paediatric Haematology and Oncology, University Hospital Motol, Prague, Czech Republic
700    1_
$a Lillicrap, David $u Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada
700    1_
$a Morfini, Massimo $u Italian Association of Haemophilia Centres, Florence, Italy
700    1_
$a Romanova, Gabriela $u Department of Clinical Haematology, University Hospital Brno, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Stephens, Derek $u Department of Clinical Research Services, The Hospital for Sick Children, Toronto, Canada
700    1_
$a Zapotocka, Ester $u Department of Paediatric Haematology and Oncology, University Hospital Motol, Prague, Czech Republic
700    1_
$a Rand, Margaret L $u Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada $u Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Canada $u Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada $u Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada $u Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada
700    1_
$a Blatny, Jan $u Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Paediatric Haematology, University Hospital Brno, Brno, Czech Republic
773    0_
$w MED00004517 $t Thrombosis and haemostasis $x 2567-689X $g Roč. 121, č. 10 (2021), s. 1326-1336
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33506480 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130202 $b ABA008
999    __
$a ok $b bmc $g 1789676 $s 1163381
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 121 $c 10 $d 1326-1336 $e 20210127 $i 2567-689X $m Thrombosis and haemostasis $n Thromb Haemost $x MED00004517
GRA    __
$a Baxalta/Takeda $p #IIRH15-27025
GRA    __
$a Baxalta U.S. Inc. $p #IIRH15-27025
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...